Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD
Gene Therapy Company Calls Off Diabetic Macular Edema Program
Executive Summary
Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.
You may also be interested in...
Could Faricimab Data Help Roche Maintain Ophthalmic Market Foothold?
The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.
Novartis Doubles Up In Optogenetics With Arctos Buy
The Basel-based major has swooped to buy fellow Swiss group Arctos in the belief that optogenetics is a promising therapeutic approach that might restore sight to patients who are legally blind.
AbbVie Extends Reach Of Regenxbio’s Wet AMD Program
The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.